Keyword: Amneal Pharmaceuticals
At least three new emergency epinephrine marketers are challenging longtime market leader Mylan and its EpiPen.
Amneal CEO Chintu Patel expects to expand a plant in New York and add 400 employees as a merger with Impax nears.
Surprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal.
Impax Labs CEO Paul Bisaro, who has extensive experience building companies through M&A, is reportedly in talks with competitor Amneal.